Recent Updates
Recently added Catalysts
CLNN Positive Sentiment

Clene to Present at H.C. Wainwright’s 5th Annual Neuro Perspectives Virtual Conference

Monday, June 24, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Clene Inc. will present at H.C. Wainwright’s 5th Annual Neuro Perspectives Virtual Conference, highlighting its initiatives in improving mitochondrial health for neurodegenerative diseases. The presentation will feature a fireside chat format and will be accessible online after the event. Additionally, Clene management is hosting one-on-one investor meetings to foster further engagement and investor interest.
Price reaction · baseline $7.926 (2024-06-21 close) · clean, no other CLNN news in the window
day 0 close · peak
-3.5%

Market Sentiment Analysis

POSITIVE FACTORS

  • Clene is presenting at a notable conference, highlighting its innovation.
  • Management engagement through 1x1 investor meetings demonstrates investor interest.
  • The focus on improving mitochondrial health positions Clene in a critical therapeutic area.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+63%
120-day peak, hindsight
Typical move
5.3%
average across 6 past catalysts
Cash runway
~11 mo
Medium dilution risk
Lead asset
CNMAu8
Phase 2 · Amyotrophic Lateral Sclerosis

Full Press Release Details

SALT LAKE CITY, June 24, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will present at H.C. Wainwright’s 5th Annual Neuro Perspectives Virtual Conference and host 1x1 investor meetings.
Time of Presentation: Available upon demand
Format: Fireside Chat
1x1 Meetings: Please contact your HCW representative
A webcast of the presentation will be available on the “Events” section of the Clene website. Alternatively, one can register online to view the webcast here.

Frequently Asked Questions

What is Clene Inc. focused on?

Clene Inc. focuses on improving mitochondrial health and protecting neuronal function.

What diseases does Clene target?

Clene aims to treat neurodegenerative diseases like ALS and MS.

When will Clene present at the conference?

Clene's presentation at the conference will be available on demand.

How can I view Clene's presentation webcast?

You can find the webcast in the 'Events' section of the Clene website.

What format will the presentation take?

The presentation will be conducted as a fireside chat.

ShareAdd on Google
Tags: CLNN Viatris Investor Conferences Healthcare Clene Inc. H.C. Wainwright neurodegenerative diseases mitochondrial health
Last updated: Jun 24, 2024

Biotech snapshot

Cash runway
$10M liquidity · $1M/mo burn
~11 mo
Medium dilution risk
Lead asset
CNMAu8Phase 2
Amyotrophic Lateral Sclerosis →

Catalyst track record

+63%
best trade around CLNN's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for CLNN.

See every catalyst's timing & PoA →